Clinical Trials Browser

Interventional × Ovarian Neoplasms × talazoparib × Clear all

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Phase 1 Recruiting

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT05071937 2025-06-22

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT04598321 2023-10-12

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Phase 1 Terminated

1 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Phase 3 Terminated

79 enrolled 18 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02326844 2020-08-18

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Phase 2 Terminated

3 enrolled 10 charts

Ovarian Neoplasms

NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn

Ovarian Neoplasms

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms